•  
  •  
  •  
  •  

2026-05-21 10:26:02

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Markets rally on Diplomatic Progress and Nvidia Beat
  • GRSE Launches Next-Gen OPV: Crafted for Vigilance, Built for Victory
  • Muthoot Finance Ranked India's No. 1 Most Trusted Financial Services Brand for 10th Consecutive Year
  • Ampere Magnus G Max by Greaves Electric Mobility Wins 'Family Scooter of the Year' at Times Drive Auto Summit and Awards 2026
  • Eris delivers 11% yoy growth in Domestic Formulations with 37% EBIDTA margin in FY26

Keywords Selected:  PSU

Research

  • SBICAPS EcoCAPSule Feb'26 : Growth To Shine As The Horizon Is Cleared Of Global Clouds
  • SBICAPS Monthly Ecocapsule Dec'24 : FY25 - A TALE OF TWO HALVES OR ONE OF FULL DESPAIR? - Executive Summary

Market Commentary

  • Bajaj Broking Market Commentary - Closing for 16th January 2026
  • Nifty Ends at Three-Week High as IT, PSU Banks Lead Rally
  • Post Market views - March 25, 2022 - Reliance Securities
  • Post Market views - March 8, 2022 - Reliance Securities

Stock Report

  • USFDA inspection concludes at Zydus' Biologics Injectable plant, Ahmedabad
  • Alembic Pharmaceuticals Limited announces USFDA Final Approval for Fingolimod Capsules, 0.5 mg
  • Balrampur Chini Mills Ltd announces ₹450 Crore Fundraising and Strategic Expansion into Gypsum Processing
  • HPCL Ensures LPG Supply Continuity, Enforces Zero-Tolerance Discipline Across Network
  • Marksans Pharma Ltd receives USFDA approval for Benzonatate Capsules USP, 100 mg & 200 mg (Rx)
  • Tembo Global Industries' Subsidiary Signs NDA with Defence PSU for Collaboration
  • Zydus receives final approval from USFDA for Cevimeline Hydrochloride Capsules 30mg
  • Natural Biogenex and Fermbox Bio Enter Strategic Framework and Manufacturing Agreements to Strengthen Fermentation-Based CDMO Capabilities
  • Eugia Pharma announces launch of Pomalidomide Capsules in the US
  • NATCO announces launch of Pomalidomide Capsules (generic of Pomalyst&®) in the U.S. market
  • Prism Johnson Ltd expands Product Range with 'Prism Chakachak' Gypsum Plaster
  • Apollo Micro Systems Ltd declared lowest bidder for orders worth Rs. 25.78 crores
  • Department of Drug Controller directs Natural Capsules Ltd to close operations of plant
  • Shelter Pharma Limited Launches D3 Cure Capsules
  • ZIM Laboratories Ltd receives approval from CDSCO - Directorate General of Health Services for Naproxen + Esomeprazole Capsules
  • Zydus receives final approval from USFDA for Diroximel Fumarate Delayed-Release Capsules, 231 mg
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval Dexlansoprazole Delayed Release Capsules, 30 mg and 60 mg
  • Zydus receives approval from China's NMPA for Venlafaxine Extended-Release Capsules, 75 mg and 150 mg
  • Zydus receives tentative approval from USFDA for Budesonide delayedrelease capsules, 4 mg
  • Aurionpro extends its winning momentum in Transaction Banking with another major Indian Public Sector Bank Deal
  • SBI strengthens presence in Tamil Nadu with the inauguration of 14 new branches
  • Lupin receives approval from U.S. FDA for Lenalidomide Capsules
  • Zydus and Synthon entered into exclusive licensing and supply agreement for Ozanimod Capsules for the U.S. market
  • DEE Development Engineers Ltd receives LoI from Indian PSU

Mutual Funds

  • DSP Mutual Fund launches DSP US Treasury Fund of Fund
  • DSP Mutual Fund launches DSP S&P BSE Sensex ETF, DSP Nifty Private Bank ETF & DSP Nifty PSU Bank ETF
  • ICICI Prudential AMC launches ICICI Prudential Nifty PSU Bank ETF NFO
  • Edelweiss Mutual Fund Launches 'Edelweiss Crisil PSU Plus SDL 50:50 Oct 2025 Index Fund'

Latest Post

  • Markets rally on Diplomatic Progress and Nvidia Beat
  • GRSE Launches Next-Gen OPV: Crafted for Vigilance, Built for Victory
  • Muthoot Finance Ranked India's No. 1 Most Trusted Financial Services Brand for 10th Consecutive Year
  • Ampere Magnus G Max by Greaves Electric Mobility Wins 'Family Scooter of the Year' at Times Drive Auto Summit and Awards 2026
  • Eris delivers 11% yoy growth in Domestic Formulations with 37% EBIDTA margin in FY26


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025